There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on MagnaChip (MX – Research Report) and Hims & Hers Health (HIMS – Research Report) with bullish sentiments.
In a report released today, Rajvindra Gill from Needham reiterated a Buy rating on MagnaChip, with a price target of $30.00. The company’s shares closed last Tuesday at $25.09, close to its 52-week high of $26.70.
According to TipRanks.com, Gill is a 5-star analyst with an average return of 14.6% and a 64.5% success rate. Gill covers the Technology sector, focusing on stocks such as Sequans Communications S A, Smart Global Holdings, and Everspin Technologies.
MagnaChip has an analyst consensus of Moderate Buy, with a price target consensus of $26.25, implying a 4.6% upside from current levels. In a report issued on March 26, Oppenheimer also assigned a Buy rating to the stock with a $25.00 price target.
Hims & Hers Health (HIMS)
In a report released today, Ivan Feinseth from Tigress Financial reiterated a Buy rating on Hims & Hers Health. The company’s shares closed last Tuesday at $12.62.
According to TipRanks.com, Feinseth is a top 100 analyst with an average return of 19.8% and a 71.7% success rate. Feinseth covers the Technology sector, focusing on stocks such as Alphabet Class A, Microsoft, and Qualcomm.
Currently, the analyst consensus on Hims & Hers Health is a Moderate Buy with an average price target of $18.00, representing a 42.6% upside. In a report issued on March 22, Citigroup also maintained a Buy rating on the stock with a $20.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.